Progressive supranuclear palsy

Sep 23, 2019

AbbVie to Present New and Updated Data From 22 Abstracts, Including Two Late-Breaking Abstracts for ABBV-951 and DUODOPA® (levodopa/carbidopa intestinal gel), at the International Congress of Parkinson's Disease and Movement Disorders®

May 20, 2019

Asceneuron Appoints Experienced CNS Clinician Dr Eric Yuen to the Board of Directors

Apr 18, 2019

TAU BIO-LOGIC Announces Humanization of Picomolar Affinity Monoclonal Antibody Targeting TauC3 Protein for the Treatment of Alzheimer's Disease and Progressive Supranuclear Palsy

Jan 17, 2019

Asceneuron Appoints Peter Van Vlasselaer as Chairman

Dec 06, 2018

Asceneuron Appoints Dr. Thomas C. Wessel as Chief Medical Officer

Nov 20, 2018

Asceneuron Initiates Neuroimaging Trial for Tau Modifier ASN120290

Nov 06, 2018

Rainwater Charitable Foundation Launches World's Largest Prize for Brain Research

Jul 18, 2018

Asceneuron's Tau Modifier ASN120290 Receives Orphan Drug Designation for Progressive Supranuclear Palsy From the FDA

Nov 15, 2017

CurePSP Support Group Initiative Goes Global This Giving Tuesday